‘‘I've lost myself,” a patient named Auguste Deter told German psychiatrist Alois Alzheimer in the early 1900s.
Her case became the foundation of Alzheimer's work on a disease that was named after him and that, more than a century later, has become an uncontrolled and little understood epidemic.
Millions of Americans, including about 7,000 Sonoma County residents, will follow Deter's descent into dementia in the coming decades unless medical research finds a cure or effective treatment for Alzheimer's disease.
As the leading edge of the baby boomer generation turns 65 this year, the so-called “silver tsunami” confronts a disease that robs people of memories — in effect their identity - and exacts an appalling cost on their loved ones and society as a whole.
There are now 5.3 million Americans living with Alzheimer's, and the cost of their care, including treatment, prescription drugs, nursing home bills and lost wages, exceeds $170 billion a year.
By 2050, the caseload will swell to 13 million Alzheimer's patients, and the cost, with inflation, could reach $500 billion. In California, the number of people with Alzheimer's is expected to nearly double from 588,208 today to more than 1.1 million by 2030.
Sonoma County's Alzheimer's population of 8,902 in 2008 is set to reach 15,799 in 2030, a 77 percent increase.
At a research center on a Novato hilltop, neurobiologist Dale Bredesen hopes to forestall that scenario with a breakthrough on Alzheimer's, possibly in as little as five years.
“We have a couple of interesting candidates,” said Bredesen, professor and founding president of the Buck Institute for Research on Aging, housed in a sleek structure west of Highway 101 at Novato.
He's talking about the results of two years of lab work spent testing thousands of compounds on brain cells and laboratory mice that have been genetically modified to develop Alzheimer's disease. Bredesen won't name the two compounds, but in three years he hopes to begin testing them on humans.